Edwards Lifesciences Corp [EW] stock is trading at $91.23, up 1.09%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The EW shares have gain 0.16% over the last week, with a monthly amount glided 4.99%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Edwards Lifesciences Corp [NYSE: EW] stock has seen the most recent analyst activity on May 30, 2024, when Goldman initiated its Buy rating and assigned the stock a price target of $107. Previously, Citigroup upgraded its rating to Buy on May 22, 2024, and elevated its price target to $105. On May 14, 2024, upgrade upgraded it’s rating to Buy. BofA Securities upgraded its rating to a Buy. Wells Fargo upgraded its rating to a Overweight but $94 remained the price target by the analyst firm on February 02, 2024. Evercore ISI downgraded its rating to In-line for this stock on January 04, 2024, and downed its price target to $77. In a note dated December 11, 2023, Citigroup downgraded an Neutral rating on this stock.
Edwards Lifesciences Corp [EW] stock has fluctuated between $60.57 and $96.12 over the past year. Currently, Wall Street analysts expect the stock to reach $110.79 within the next 12 months. Edwards Lifesciences Corp [NYSE: EW] shares were valued at $91.23 at the most recent close of the market. An investor can expect a potential return of 21.44% based on the average EW price forecast.
Analyzing the EW fundamentals
Edwards Lifesciences Corp [NYSE:EW] reported sales of 6.14B for the trailing twelve months, which represents a growth of 9.50%. Gross Profit Margin for this corporation currently stands at 0.77% with Operating Profit Margin at 0.26%, Pretax Profit Margin comes in at 0.26%, and Net Profit Margin reading is 0.23%. To continue investigating profitability, this company’s Return on Assets is posted at 0.15, Equity is 0.21 and Total Capital is 0.18. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.09.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 90.23 points at the first support level, and at 89.24 for the second support level. However, for the 1st resistance point, the stock is sitting at 91.79, and for the 2nd resistance point, it is at 92.36.
Ratios To Look Out For
For context, Edwards Lifesciences Corp’s Current Ratio is 3.75. As well, the Quick Ratio is 2.67, while the Cash Ratio is 1.1. Considering the valuation of this stock, the price to sales ratio is 8.95, the price to book ratio is 7.72 and price to earnings (TTM) ratio is 39.21.
Transactions by insiders
Recent insider trading involved Ullem Scott B., CVP, Chief Financial Officer, that happened on Jun 20 ’24 when 5625.0 shares were sold. CVP, JAPAC, Lippis Daniel J. completed a deal on Jun 20 ’24 to sell 535.0 shares. Meanwhile, CVP,Strategy/Corp Development BOBO DONALD E JR sold 5000.0 shares on Jun 12 ’24.
